Summer 2020 Vol. 10 Issue 02
-
From the Editor-in-Chief
Measuring a Cancer Drug’s EffectivenessSurrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?
by William G. Nelson, MD, PhD
-
Your Cancer Guide
Not Our First RodeoDuring the COVID-19 pandemic, cancer survivors can tap into familiar lessons of resiliency.
by Hester Hill Schnipper
-
Caregiving With Confidence
The Power of AngerAccepting this emotion can be the first step in channeling it for a constructive purpose.
by Karen J. Bannan
-
Policy Matters
Racial and Ethnic Disparities in Multiple Myeloma Clinical TrialsThe AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.
by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD
-
A Delicate Balance
Cancer patients with chronic pain and the physicians who treat them strive to address pain while avoiding potential opioid abuse and addiction.
by Charlotte Huff
-
Keeping CLL in Check
With recent advances in targeted treatments, people diagnosed with chronic lymphocytic leukemia have more options to manage the disease.
by Kendall K. Morgan
-
Robotic Surgery and Cancer
Using robotic assistants for cancer surgery has become commonplace. Whether cancer patients benefit when a surgeon uses a robot remains unclear.
by Sue Rochman
-
Survivor Profile
Sharing Her StrengthDiagnosed with two cancers prior to turning 40, Rebecca Esparza uses her voice to advocate for policy changes to help people affected by cancer.
by Lindsey Konkel
-
Q&A
Taking the Long ViewIn her first book, journalist and breast cancer survivor Kate Pickert traces the winding road of cancer research and patient advocacy.
by Marci A. Landsmann
-
Sound Advice
Your Questions, Our AnswersWeight gain during treatment, conversations about sex, and what to know about a loved one's insurance.
-
Facts and Stats
A Quarter Century of Progress Against Lung CancerWhile advances have been made in treating lung cancer and risk reduction, there is still plenty of work to be done.
by Bradley Jones
Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin